244 related articles for article (PubMed ID: 8471778)
1. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Blume KG; Kopecky KJ; Henslee-Downey JP; Forman SJ; Stiff PJ; LeMaistre CF; Appelbaum FR
Blood; 1993 Apr; 81(8):2187-93. PubMed ID: 8471778
[TBL] [Abstract][Full Text] [Related]
2. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Blume KG; Long GD; Negrin RS; Chao NJ; Kusnierz-Glaz C; Amylon MD
Bone Marrow Transplant; 1994; 14 Suppl 4():S9-10. PubMed ID: 7728133
[TBL] [Abstract][Full Text] [Related]
3. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
Devergie A; Blaise D; Attal M; Tigaud JD; Jouet JP; Vernant JP; Bordigoni P; Ifrah N; Dauriac C; Cahn JY
Blood; 1995 Apr; 85(8):2263-8. PubMed ID: 7718899
[TBL] [Abstract][Full Text] [Related]
5. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.
Toubai T; Tanaka J; Mori A; Hashino S; Kobayashi S; Ota S; Miura Y; Kato N; Kahata K; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Toyoshima N; Asaka M; Imamura M
Clin Transplant; 2004 Oct; 18(5):552-7. PubMed ID: 15344959
[TBL] [Abstract][Full Text] [Related]
7. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
[TBL] [Abstract][Full Text] [Related]
8. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
[TBL] [Abstract][Full Text] [Related]
9. Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up.
Aschan J; Carlens S; Hägglund H; Klaesson S; Mattsson J; Remberger M
Clin Transplant; 1999 Dec; 13(6):512-9. PubMed ID: 10617242
[TBL] [Abstract][Full Text] [Related]
10. The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.
Rosales F; Naparstek E; Varadi G; Or R; Slavin S; Nagler A
Leuk Res; 1999 Oct; 23(10):947-52. PubMed ID: 10573141
[TBL] [Abstract][Full Text] [Related]
11. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
14. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
15. Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation.
Shah AJ; Lenarsky C; Kapoor N; Crooks GM; Kohn DB; Parkman R; Epport K; Wilson K; Weinberg K
J Pediatr Hematol Oncol; 2004 Feb; 26(2):91-7. PubMed ID: 14767194
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia.
Dusenbery KE; Daniels KA; McClure JS; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):119-28. PubMed ID: 7995742
[TBL] [Abstract][Full Text] [Related]
17. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.
Radich JP; Sanders JE; Buckner CD; Martin PJ; Petersen FB; Bensinger W; McDonald GB; Mori M; Schoch G; Hansen JA
J Clin Oncol; 1993 Feb; 11(2):304-13. PubMed ID: 8426208
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans.
Kim I; Park S; Kim BK; Chang HM; Bang SM; Byun JH; Kim DJ; Min WS; Kim HJ; Kim CC
Clin Transplant; 2001 Jun; 15(3):167-72. PubMed ID: 11389706
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience.
Dusenbery KE; Steinbuch M; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Litz C; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):335-43. PubMed ID: 8892457
[TBL] [Abstract][Full Text] [Related]
20. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
